[ Teewinot Life Sciences raises $12.3M in Series B ]

Teewinot Life Sciences has raised $12.3 million in Series B funding.

Founded in 2015, Teewinot Life Sciences  is a global biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids. Teewinot has developed patent protected processes for production of pure cannabinoids by means of biocatalysis and synthetic biology.

The capital raised will be used for a variety of activities including enhancement and acceleration of research and development activities, expanding business development opportunities, and adding to the existing patent portfolio.

Funding  Series B
Founded  2015
Country  USA
City  Tampa, Florida
Founder / CEO  Jeffrey M. Korentur
Deal Size  $12.3M
Investors  Tuatara Capital
Previous Investors  same as above 

[adyen action=”checkout_button”]